



### A TERMINATED TRIAL IS NOT NECESSARILY A FAILED DRUG.

#### THE PROBLEM


##### Why do clinical trials fail?



- "Business decision"
- "strategic decision"
- "sponsor decision"
- "portfolio prioritization"
- "lack of funding"
- "administrative reasons"
- "company restructuring"
- "acquisition"
- "program discontinued"
- "study drug unavailable"
- "commercial reasons"
- "organizational reasons"
- "investigator left"
- "slow enrollment"
- "poor accrual"
- "insufficient recruitment"
- "trial-design failure"



Many trials fail for reasons other than safety and efficacy!




#### THE PLATFORM




We created a digital workflow that utilizes advanced data analysis to build an evidence-backed investigation around each discontinued asset, with recommended FDA-approval and commercialization paths.



DISCOVER



INVESTIGATE



RESURRECT

KEY SOURCES:



PROPRIETARY ALGORITHM DESIGNED TO IDENTIFY, VALIDATE, LICENSE, AND ADVANCE HIGH-POTENTIAL THERAPEUTIC ASSETS TOWARD FDA APPROVAL AND COMMERCIALIZATION.

#### CASE STUDIES

1. **MRTX-1133** is a selective KRAS G12D inhibitor developed for molecularly defined cancers harboring KRAS G12D mutations. Clinical development was discontinued before definitive efficacy evaluation, with publicly reported limitations centered on formulation and pharmacokinetic variability rather than target invalidation. The program therefore represents a precision-oncology asset with strong biological rationale and a potentially addressable development barrier.

2. **TLY012** is a DR5/TRAIL-pathway therapeutic with potential relevance in precision oncology through selective targeting of activated stromal and fibrotic components of the tumor microenvironment. Its mechanism may be particularly relevant in treatment-resistant tumors where stromal remodeling and rational combination strategies could improve therapeutic response.

3. **PF-04136309**, a CCR2 chemokine receptor antagonist combined with standard first-line gemcitabine/nab-paclitaxel in metastatic pancreatic cancer, was terminated by Pfizer as part of a 36-program portfolio sweep, with the sponsor explicitly stating in the registry that the decision was not due to safety or efficacy — a textbook company-level, non-scientific stop with a published Phase 1b dataset already in hand.

4. **Veledimex**, an inducible IL-12 expression activator, was halted for business reasons before its immunomodulatory hypothesis in glioblastoma could be clinically tested, representing a high-impact, orphan-eligible oncology asset whose exposure and biomarker strategy are tractable.

To learn more about these potentially recoverable assets, visit our website by scanning the QR code:



Scan the QR code to share your feedback and help us improve our website. Proof of completion will result in a **\$20 Dunkin' gift card** from James El-Deiry at the Resurrect Therapeutics Table Display.

[resurrect-therapeutics.org](https://resurrect-therapeutics.org)

Providence, RI

More Engaging Features:  
Biotech/Pharma News &  
Social Media Platform



ChatGPT & Grok were utilized in the creation of several aspects of this poster